查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1600875

基因治疗市场：按类型、载体类型、应用划分 - 2025-2030 年全球预测

Gene Therapy Market by Type (Antigen Gene Therapy, Cancer Gene Therapy, Cytokine Gene Therapy), Vector Type (Non-viral Vectors, Viral Vectors), Application - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年基因治疗市值为56.7亿美元，预计2024年将达70.5亿美元，复合年增长率为27.15%，到2030年将达到304.8亿美元。

基因疗法是一种创新的医学方法，旨在透过修改遗传物质来治疗或预防疾病，在对抗遗传性疾病、某些癌症和病毒感染疾病方面具有巨大的潜力。这种需求源自于传统治疗方法的局限性，无法解决潜在的遗传原因。应用包括罕见遗传疾病的治疗、癌症治疗和血友病治疗，显着改善患者的治疗效果。最终用途主要包括临床研究、医院和专科诊所。

主要市场统计
基准年[2023] 56.7亿美元
预测年份 [2024] 70.5亿美元
预测年份 [2030] 304.8亿美元
复合年增长率（%） 27.15%

由于基因工程的进步和研发投资的增加，基因治疗市场正在经历强劲成长。关键的成长要素包括监管支持、遗传疾病盛行率的增加以及 CRISPR 等技术创新。此外，不断增长的新型疗法管道和市场参与企业之间的策略联盟为业务扩张提供了潜在的机会。公司应专注于儿科适应症和新兴市场，以利用未满足的需求和政府奖励。然而，限制因素包括高成本、道德问题、监管障碍和製造复杂性，这对扩充性和市场进入缓慢构成了挑战。此外，长期安全性和有效性需要持续审查。

创新追求集中在改进递送载体以提高精度和效率、开发个人化医疗方法以及利用人工智慧提高基因编辑精度和预测结果等领域。儘管市场正在快速发展，但由于全球监管和定价挑战的不同，它仍然分散。公司可以透过投资合作研究来改进基因技术并扩大治疗范围来取得成功。严格的临床试验和伙伴关係的需要描绘了一幅需要坚韧和策略远见的图景。总体而言，专注于克服现有挑战为公司提供了创新、优化成本和提高全球基因治疗解决方案的可及性的机会。

市场动态：揭示快速发展的基因治疗市场的关键市场洞察

供需的动态交互作用正在改变基因治疗市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助企业了解消费行为及其对製造业的影响。

  • 市场驱动因素
    • 慢性病流行和治疗中心数量不断增加
    • 政府对基因治疗的支持与道德接受
  • 市场限制因素
    • 基因治疗相关的高成本
  • 市场机会
    • 罕见疾病研发进展及基因治疗进展
    • 创新的支付模式和有利的监管核准
  • 市场挑战
    • 新基因疗法的潜在副作用和道德担忧

波特的五力策略工具驾驭基因治疗市场

波特的五力架构是了解基因治疗市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解基因治疗市场的外部影响

外部宏观环境因素在塑造基因治疗市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解基因治疗市场的竞争状况

对基因治疗市场的详细市场占有率分析可以对供应商绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV定位矩阵基因治疗市场供应商绩效评估

FPNV定位矩阵是评估基因疗法市场供应商的重要工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。四个象限清楚且准确地划分供应商，帮助使用者辨识最能满足其策略目标的合作伙伴和解决方案。

本报告提供了涵盖关键重点领域的全面市场分析：

1. 市场渗透率：对当前市场环境的详细回顾，包括行业主要企业的大量资料。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点关注可望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 慢性病盛行率上升，治疗中心数量迅速增加
      • 政府对基因治疗的治疗和道德接受的支持
    • 抑制因素
      • 基因治疗相关的高成本
    • 机会
      • 持续研究和开发罕见疾病和基因治疗进展
      • 创新的支付模式和有利的监管核准
    • 任务
      • 新基因疗法的潜在副作用和道德担忧
  • 市场区隔分析
    • 类型： 癌症盛行率 癌症治疗 基因治疗
    • 载体类型：病毒载体的大量利用提高了基因递送至细胞的效率
    • 应用：基因疗法作为治疗心血管疾病的创新方法的潜在应用
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境
  • 客户客製化

第六章 基因治疗市场：依类型

  • 抗原基因治疗
  • 癌症基因治疗
  • 细胞激素基因治疗
  • 自杀基因治疗
  • 抑癌基因治疗

第七章基因治疗市场：依载体类型

  • 非病毒载体
  • 病毒载体

第八章基因治疗市场：依应用分类

  • 心血管疾病
  • 遗传疾病
  • 感染疾病
  • 神经系统疾病
  • 肿瘤性疾病

第九章 北美和南美基因治疗市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太基因治疗市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章 欧洲、中东和非洲的基因治疗市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • Charles River 宣布推出贷款平台以加速基于 LVV 的基因疗法製造
    • Laurus 在印度推出基因治疗资产
    • Bluebird Bio 准备推出基因疗法作为镰状细胞疾病的应用方法

公司名单

  • Cellectis, Inc.
  • Novartis AG
  • Biogen Inc.
  • AnGes, Inc.
  • Orchard Therapeutics PLC
  • Poseida Therapeutics, Inc.
  • Astellas Gene Therapies
  • Sarepta Therapeutics, Inc.
  • Uniqure NV
  • Applied Genetic Technologies Corporation
  • Mustang Bio
  • Abeona Therapeutics Inc.
  • Adaptimmune Therapeutics PLC
  • Shenzhen SiBiono GeneTech Co. Ltd.
  • Spark Therapeutics, Inc.
  • Ionis Pharmaceuticals, Inc.
  • Amgen Inc.
  • Sangamo Therapeutics, Inc.
  • AGC Biologics.
  • Merck & Co., Inc.
  • American Gene Technologies Inc.
  • Editas Medicine, Inc.
  • Bluebird Bio, Inc.
  • Alnylam Pharmaceuticals, Inc.
  • Human Stem Cells Institute
Product Code: MRR-437517DB6C62

The Gene Therapy Market was valued at USD 5.67 billion in 2023, expected to reach USD 7.05 billion in 2024, and is projected to grow at a CAGR of 27.15%, to USD 30.48 billion by 2030.

Gene therapy, a transformative medical approach aiming to treat or prevent diseases by modifying genetic material, holds immense potential in addressing inherited disorders, certain cancers, and viral infections. Its necessity arises from the limitation of traditional therapies unable to address root genetic causes. Applications include the treatment of rare genetic disorders, cancer therapy, and hemophilia, significantly enhancing patient outcomes. In terms of end-use, gene therapy primarily finds application in clinical research, hospitals, and specialty clinics.

KEY MARKET STATISTICS
Base Year [2023] USD 5.67 billion
Estimated Year [2024] USD 7.05 billion
Forecast Year [2030] USD 30.48 billion
CAGR (%) 27.15%

The gene therapy market is experiencing robust growth, driven by advancements in genetic engineering and increased investment in research and development. Key growth factors include regulatory support, an increase in the prevalence of genetic diseases, and technological innovations like CRISPR. Additionally, the growing pipeline of novel therapies and strategic collaborations among market players present potential opportunities for expansion. Companies should focus on pediatric indications and emerging markets to leverage unmet needs and governmental incentives. However, limitations include high costs, ethical concerns, regulatory hurdles, and manufacturing complexities, which challenge scalability and delay market entry. Moreover, long-term safety and efficacy continue to be under scrutiny.

Innovative exploration can be concentrated in areas such as improving delivery vectors for better precision and efficiency, developing personalized medicine approaches, and utilizing AI for gene-editing precision and forecasting outcomes. The market features rapid advancements but remains fragmented due to varying global regulations and price-setting challenges. Businesses can thrive by investing in collaborative research to refine genetic technologies and expand therapeutic scopes. The necessity for rigorous clinical trials and partnerships depicts a landscape demanding persistence and strategic foresight. All in all, with a focus on overcoming existing challenges, businesses have the opportunity to innovate, optimize costs, and improve the accessibility of gene therapy solutions globally.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Gene Therapy Market

The Gene Therapy Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing Prevalence of Chronic Diseases and Upsurge in Number of Gene Therapy Treatment Centers
    • Government Support and Ethical Acceptance of Gene Therapy For Treatments
  • Market Restraints
    • High Costs Associated with Gene Therapies
  • Market Opportunities
    • Ongoing Research & Development in Orphan Diseases and Advancements in Gene Therapy
    • Innovative Payment Models and Favorable Regulatory Approvals
  • Market Challenges
    • Potential Harmful Effects and Moral Concerns Regarding New Gene Therapy

Porter's Five Forces: A Strategic Tool for Navigating the Gene Therapy Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Gene Therapy Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Gene Therapy Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Gene Therapy Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Gene Therapy Market

A detailed market share analysis in the Gene Therapy Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Gene Therapy Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Gene Therapy Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Gene Therapy Market, highlighting leading vendors and their innovative profiles. These include Cellectis, Inc., Novartis AG, Biogen Inc., AnGes, Inc., Orchard Therapeutics PLC, Poseida Therapeutics, Inc., Astellas Gene Therapies, Sarepta Therapeutics, Inc., Uniqure N.V., Applied Genetic Technologies Corporation, Mustang Bio, Abeona Therapeutics Inc., Adaptimmune Therapeutics PLC, Shenzhen SiBiono GeneTech Co. Ltd., Spark Therapeutics, Inc., Ionis Pharmaceuticals, Inc., Amgen Inc., Sangamo Therapeutics, Inc., AGC Biologics., Merck & Co., Inc., American Gene Technologies Inc., Editas Medicine, Inc., Bluebird Bio, Inc., Alnylam Pharmaceuticals, Inc., and Human Stem Cells Institute.

Market Segmentation & Coverage

This research report categorizes the Gene Therapy Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Antigen Gene Therapy, Cancer Gene Therapy, Cytokine Gene Therapy, Suicide Gene Therapy, and Tumor Suppressor Gene Therapy.
  • Based on Vector Type, market is studied across Non-viral Vectors and Viral Vectors.
  • Based on Application, market is studied across Cardiovascular Diseases, Genetic Diseases, Infectious Diseases, Neurological Diseases, and Oncological Disorders.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing Prevalence of Chronic Diseases and Upsurge in Number of Gene Therapy Treatment Centers
      • 5.1.1.2. Government Support and Ethical Acceptance of Gene Therapy For Treatments
    • 5.1.2. Restraints
      • 5.1.2.1. High Costs Associated with Gene Therapies
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing Research & Development in Orphan Diseases and Advancements in Gene Therapy
      • 5.1.3.2. Innovative Payment Models and Favorable Regulatory Approvals
    • 5.1.4. Challenges
      • 5.1.4.1. Potential Harmful Effects and Moral Concerns Regarding New Gene Therapy
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Type: Prevalence of cancer gene therapy for cancer treatment
    • 5.2.2. Vector Type: Significant utilization of viral vector providing higher efficiency in delivering genes into cells
    • 5.2.3. Application: Potential adoption of gene therapy as a revolutionary approach to treating cardiovascular diseases
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental
  • 5.5. Client Customization

6. Gene Therapy Market, by Type

  • 6.1. Introduction
  • 6.2. Antigen Gene Therapy
  • 6.3. Cancer Gene Therapy
  • 6.4. Cytokine Gene Therapy
  • 6.5. Suicide Gene Therapy
  • 6.6. Tumor Suppressor Gene Therapy

7. Gene Therapy Market, by Vector Type

  • 7.1. Introduction
  • 7.2. Non-viral Vectors
  • 7.3. Viral Vectors

8. Gene Therapy Market, by Application

  • 8.1. Introduction
  • 8.2. Cardiovascular Diseases
  • 8.3. Genetic Diseases
  • 8.4. Infectious Diseases
  • 8.5. Neurological Diseases
  • 8.6. Oncological Disorders

9. Americas Gene Therapy Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Gene Therapy Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Gene Therapy Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. Charles River Unveils Lentivation Platform to Expedite LVV-based Gene Therapy Manufacturing
    • 12.3.2. Laurus to launch Gene Therapy Assets in India
    • 12.3.3. Bluebird bio Lays Gene Therapy Launch Groundwork As Sickle Cell Application Nears

Companies Mentioned

  • 1. Cellectis, Inc.
  • 2. Novartis AG
  • 3. Biogen Inc.
  • 4. AnGes, Inc.
  • 5. Orchard Therapeutics PLC
  • 6. Poseida Therapeutics, Inc.
  • 7. Astellas Gene Therapies
  • 8. Sarepta Therapeutics, Inc.
  • 9. Uniqure N.V.
  • 10. Applied Genetic Technologies Corporation
  • 11. Mustang Bio
  • 12. Abeona Therapeutics Inc.
  • 13. Adaptimmune Therapeutics PLC
  • 14. Shenzhen SiBiono GeneTech Co. Ltd.
  • 15. Spark Therapeutics, Inc.
  • 16. Ionis Pharmaceuticals, Inc.
  • 17. Amgen Inc.
  • 18. Sangamo Therapeutics, Inc.
  • 19. AGC Biologics.
  • 20. Merck & Co., Inc.
  • 21. American Gene Technologies Inc.
  • 22. Editas Medicine, Inc.
  • 23. Bluebird Bio, Inc.
  • 24. Alnylam Pharmaceuticals, Inc.
  • 25. Human Stem Cells Institute

LIST OF FIGURES

  • FIGURE 1. GENE THERAPY MARKET RESEARCH PROCESS
  • FIGURE 2. GENE THERAPY MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL GENE THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL GENE THERAPY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL GENE THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL GENE THERAPY MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL GENE THERAPY MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL GENE THERAPY MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL GENE THERAPY MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS GENE THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS GENE THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES GENE THERAPY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES GENE THERAPY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC GENE THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC GENE THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA GENE THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA GENE THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. GENE THERAPY MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. GENE THERAPY MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. GENE THERAPY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL GENE THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL GENE THERAPY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. GENE THERAPY MARKET DYNAMICS
  • TABLE 7. GLOBAL GENE THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL GENE THERAPY MARKET SIZE, BY ANTIGEN GENE THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL GENE THERAPY MARKET SIZE, BY CANCER GENE THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL GENE THERAPY MARKET SIZE, BY CYTOKINE GENE THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL GENE THERAPY MARKET SIZE, BY SUICIDE GENE THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL GENE THERAPY MARKET SIZE, BY TUMOR SUPPRESSOR GENE THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL GENE THERAPY MARKET SIZE, BY GENETIC DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL GENE THERAPY MARKET SIZE, BY NEUROLOGICAL DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS GENE THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA GENE THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL GENE THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 32. CANADA GENE THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. CANADA GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. CANADA GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 35. MEXICO GENE THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. MEXICO GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. MEXICO GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES GENE THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. UNITED STATES GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. UNITED STATES GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 41. UNITED STATES GENE THERAPY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC GENE THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. ASIA-PACIFIC GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. ASIA-PACIFIC GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 45. ASIA-PACIFIC GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 46. AUSTRALIA GENE THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. AUSTRALIA GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. AUSTRALIA GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 49. CHINA GENE THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. CHINA GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. CHINA GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 52. INDIA GENE THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. INDIA GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. INDIA GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 55. INDONESIA GENE THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. INDONESIA GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. INDONESIA GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 58. JAPAN GENE THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. JAPAN GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. JAPAN GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 61. MALAYSIA GENE THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. MALAYSIA GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. MALAYSIA GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 64. PHILIPPINES GENE THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. PHILIPPINES GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. PHILIPPINES GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 67. SINGAPORE GENE THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. SINGAPORE GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. SINGAPORE GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 70. SOUTH KOREA GENE THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. SOUTH KOREA GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. SOUTH KOREA GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 73. TAIWAN GENE THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. TAIWAN GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. TAIWAN GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 76. THAILAND GENE THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. THAILAND GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. THAILAND GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 79. VIETNAM GENE THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. VIETNAM GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. VIETNAM GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA GENE THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 85. EUROPE, MIDDLE EAST & AFRICA GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 86. DENMARK GENE THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. DENMARK GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. DENMARK GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 89. EGYPT GENE THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. EGYPT GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. EGYPT GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 92. FINLAND GENE THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. FINLAND GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. FINLAND GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 95. FRANCE GENE THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. FRANCE GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. FRANCE GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 98. GERMANY GENE THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. GERMANY GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. GERMANY GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 101. ISRAEL GENE THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. ISRAEL GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. ISRAEL GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 104. ITALY GENE THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. ITALY GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. ITALY GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 107. NETHERLANDS GENE THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. NETHERLANDS GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. NETHERLANDS GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 110. NIGERIA GENE THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. NIGERIA GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. NIGERIA GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 113. NORWAY GENE THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. NORWAY GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. NORWAY GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 116. POLAND GENE THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. POLAND GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. POLAND GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 119. QATAR GENE THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. QATAR GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. QATAR GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 122. RUSSIA GENE THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. RUSSIA GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. RUSSIA GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 125. SAUDI ARABIA GENE THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. SAUDI ARABIA GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. SAUDI ARABIA GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH AFRICA GENE THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. SOUTH AFRICA GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. SOUTH AFRICA GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 131. SPAIN GENE THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. SPAIN GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. SPAIN GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 134. SWEDEN GENE THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. SWEDEN GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. SWEDEN GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 137. SWITZERLAND GENE THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. SWITZERLAND GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. SWITZERLAND GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 140. TURKEY GENE THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. TURKEY GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. TURKEY GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED ARAB EMIRATES GENE THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED ARAB EMIRATES GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED ARAB EMIRATES GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED KINGDOM GENE THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. UNITED KINGDOM GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. UNITED KINGDOM GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 149. GENE THERAPY MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 150. GENE THERAPY MARKET, FPNV POSITIONING MATRIX, 2023